Susan Halabi on Sub Group Analysis

March 14, 2017

Susan Halabi presented, "Should we be lumpers or slicers?" as part of the castration-sensitive naive prostate cancer session at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerland.  Alicia Morgans, MD interviewed Susan on the utility of the sub group analysis and how clinicians need to think about those in clinical trials.  In addition, a discussion around the value of the APCCC and the forum it provides for data sharing and collaboration. 

Susan Halabi, PhD, is Professor, Department of Biostatistics and Bioinformatics, Duke University and Faculty Statistician, Genitourinary Committee (GU), for the Alliance for Clinical Trials in Oncology (formerly the Cancer and Leukemia Group B), an National Cancer Institute (NCI)-sponsored cancer cooperative group. She is actively involved in clinical trial design, conduct and analysis, and biomarker validation and has published over 140 articles in medical and statistical journals. In addition, she has extensive experience and maintains a research portfolio in model development, validation and exploring surrogate endpoints of overall survival in prostate and renal cancer.  She has been a member of the NCI GU Steering Committee since its inception in 2008 and is a member of the Renal, Bladder and Prostate Task Forces. Dr. Halabi has served on study sections and review committees for the NCI, other NIH institutes and the Food and Drug Administration, and has also served as an officer for the International Biometric Society, the American Statistical Association, and the Society of Clinical Trials.

Alicia Morgans

Access to all Advanced Prostate Cancer Consensus Conference Video Coverage 

Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer